Alexander Rossi1, Kristin Berger1, Honglei Chen2, Douglas Leslie3, Richard B Mailman4,5, Xuemei Huang4,5. 1. Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 2. Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA. 3. Department of Public Health Sciences, Pennsylvania State University, Hershey, Pennsylvania, USA. 4. Department of Neurology, Pennsylvania State University, Hershey, Pennsylvania, USA. 5. Department of Pharmacology, Pennsylvania State University, Hershey, Pennsylvania, USA.
Abstract
OBJECTIVE: Previous studies have estimated future PD prevalence based on population aging. This study revisits that projection by accounting for the potential impact of declining rates of smoking. METHODS: The age- and gender-stratified smoking prevalence in the United States from 2000 to 2040 were obtained from the U.S. Census Bureau and the U.S. Surgeon General's Smoking Report. PD prevalence was estimated based on population aging with and without an account of the impact of declining smoking rates. Relative risks of 0.56 and 0.78 were applied for current and former smokers, respectively. RESULTS: Accounting for aging alone, ∼700,000 PD cases are predicted by 2040. After accounting for the declining smoking prevalence, ∼770,000 cases, an increase of ∼10% over the estimate without smoking, is predicted. CONCLUSIONS: If the epidemiological association of smoking and PD is causal, projecting future cases without considering smoking may underestimate disease burden, underscoring the urgency of adequate resource allocation.
OBJECTIVE: Previous studies have estimated future PD prevalence based on population aging. This study revisits that projection by accounting for the potential impact of declining rates of smoking. METHODS: The age- and gender-stratified smoking prevalence in the United States from 2000 to 2040 were obtained from the U.S. Census Bureau and the U.S. Surgeon General's Smoking Report. PD prevalence was estimated based on population aging with and without an account of the impact of declining smoking rates. Relative risks of 0.56 and 0.78 were applied for current and former smokers, respectively. RESULTS: Accounting for aging alone, ∼700,000 PD cases are predicted by 2040. After accounting for the declining smoking prevalence, ∼770,000 cases, an increase of ∼10% over the estimate without smoking, is predicted. CONCLUSIONS: If the epidemiological association of smoking and PD is causal, projecting future cases without considering smoking may underestimate disease burden, underscoring the urgency of adequate resource allocation.
Authors: Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: Delaram Safarpour; Dylan P Thibault; Cori L DeSanto; Cynthia M Boyd; E Ray Dorsey; Brad A Racette; Allison W Willis Journal: Neurology Date: 2015-07-02 Impact factor: 9.910
Authors: E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner Journal: Neurology Date: 2006-11-02 Impact factor: 9.910
Authors: Allison Hicks; Kala Phillips; Chelsea Siwik; Paul Salmon; Irene Litvan; Megan E Jablonski; J Vincent Filoteo; Karen Kayser; Sandra E Sephton Journal: Qual Life Res Date: 2019-06-14 Impact factor: 4.147
Authors: Mohamed El-Gamal; Mohamed Salama; Lyndsey E Collins-Praino; Irina Baetu; Ahmed M Fathalla; Amira M Soliman; Wael Mohamed; Ahmed A Moustafa Journal: Neurotox Res Date: 2021-03-25 Impact factor: 3.911
Authors: Jacqueline M Godbe; Ronit Freeman; Lena F Burbulla; Jacob Lewis; Dimitri Krainc; Samuel I Stupp Journal: ACS Biomater Sci Eng Date: 2020-01-17